These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35982335)

  • 21. Clinical Approach to Mast Cell Activation Syndrome: A Practical Overview.
    Matito A; Escribese MM; Longo N; Mayorga C; Luengo-Sánchez O; Pérez-Gordo M; Matheu V; Labrador-Horrillo M; Pascal M; Seoane-Reula ME;
    J Investig Allergol Clin Immunol; 2021 Dec; 31(6):461-470. PubMed ID: 33541851
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease.
    Miller MK; Zimmerman SA; Schultz WH; Ware RE
    J Pediatr Hematol Oncol; 2001; 23(5):306-8. PubMed ID: 11464988
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patients with mast cell activation symptoms and elevated baseline serum tryptase level have unique bone marrow morphology.
    Giannetti MP; Akin C; Hufdhi R; Hamilton MJ; Weller E; van Anrooij B; Lyons JJ; Hornick JL; Pinkus G; Castells M; Pozdnyakova O
    J Allergy Clin Immunol; 2021 Apr; 147(4):1497-1501.e1. PubMed ID: 33248113
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mast Cell Activation Syndrome.
    Frieri M
    Clin Rev Allergy Immunol; 2018 Jun; 54(3):353-365. PubMed ID: 25944644
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Neuropsychiatric Manifestations of Mast Cell Activation Syndrome and Response to Mast-Cell-Directed Treatment: A Case Series.
    Weinstock LB; Nelson RM; Blitshteyn S
    J Pers Med; 2023 Oct; 13(11):. PubMed ID: 38003876
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Mast cell activation symptoms are prevalent in Long-COVID.
    Weinstock LB; Brook JB; Walters AS; Goris A; Afrin LB; Molderings GJ
    Int J Infect Dis; 2021 Nov; 112():217-226. PubMed ID: 34563706
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hydroxyurea for recurrent surgery and radiation refractory meningioma: a retrospective case series.
    Chamberlain MC; Johnston SK
    J Neurooncol; 2011 Sep; 104(3):765-71. PubMed ID: 21318318
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety of Eluxadoline in Patients with Irritable Bowel Syndrome with Diarrhea.
    Cash BD; Lacy BE; Schoenfeld PS; Dove LS; Covington PS
    Am J Gastroenterol; 2017 Feb; 112(2):365-374. PubMed ID: 27922029
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Post-HPV-Vaccination Mast Cell Activation Syndrome: Possible Vaccine-Triggered Escalation of Undiagnosed Pre-Existing Mast Cell Disease?
    Afrin LB; Dempsey TT; Weinstock LB
    Vaccines (Basel); 2022 Jan; 10(1):. PubMed ID: 35062788
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The HYDILE trial: efficacy and tolerance of a quadruple combination of reverse transcriptase inhibitors versus the same regimen plus hydroxyurea or hydroxyurea and interleukin-2 in HIV-infected patients failing protease inhibitor-based combinations.
    Lafeuillade A; Hittinger G; Chadapaud S; Maillefet S; Rieu A; Poggi C
    HIV Clin Trials; 2002; 3(4):263-71. PubMed ID: 12187499
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between mast cell activation syndrome, postural tachycardia syndrome, and Ehlers-Danlos syndrome.
    Wang E; Ganti T; Vaou E; Hohler A
    Allergy Asthma Proc; 2021 May; 42(3):243-246. PubMed ID: 33980338
    [No Abstract]   [Full Text] [Related]  

  • 32. Hydroxyurea for recurrent surgery and radiation refractory high-grade meningioma.
    Chamberlain MC
    J Neurooncol; 2012 Apr; 107(2):315-21. PubMed ID: 22127733
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Safety of hydroxyurea in children with sickle cell anemia: results of the HUG-KIDS study, a phase I/II trial. Pediatric Hydroxyurea Group.
    Kinney TR; Helms RW; O'Branski EE; Ohene-Frempong K; Wang W; Daeschner C; Vichinsky E; Redding-Lallinger R; Gee B; Platt OS; Ware RE
    Blood; 1999 Sep; 94(5):1550-4. PubMed ID: 10477679
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adverse effects of hydroxyurea in beta-thalassemia intermedia patients: 10 years' experience.
    Karimi M; Cohan N; Mousavizadeh K; Falahi MJ; Haghpanah S
    Pediatr Hematol Oncol; 2010 Apr; 27(3):205-11. PubMed ID: 20367264
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Idiopathic mast cell activation syndrome and radiation therapy: a case study, literature review, and discussion of mast cell disorders and radiotherapy.
    Landy RE; Stross WC; May JM; Kaleem TA; Malouff TD; Waddle MR; Vallow LA
    Radiat Oncol; 2019 Dec; 14(1):222. PubMed ID: 31818306
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospective longitudinal follow-up of children with sickle cell disease treated with hydroxyurea since infancy.
    Thomas R; Dulman R; Lewis A; Notarangelo B; Yang E
    Pediatr Blood Cancer; 2019 Sep; 66(9):e27816. PubMed ID: 31157521
    [TBL] [Abstract][Full Text] [Related]  

  • 37. On the use of hydroxyurea/erythropoietin combination therapy for sickle cell disease.
    el-Hazmi MA; al-Momen A; Kandaswamy S; Huraib S; Harakati M; al-Mohareb F; Warsy AS
    Acta Haematol; 1995; 94(3):128-34. PubMed ID: 7502628
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adverse Events in Pediatric Patients Receiving Long-Term Outpatient Antimicrobials.
    Olson SC; Smith S; Weissman SJ; Kronman MP
    J Pediatric Infect Dis Soc; 2015 Jun; 4(2):119-25. PubMed ID: 26407410
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Diagnosis, Classification and Management of Mast Cell Activation Syndromes (MCAS) in the Era of Personalized Medicine.
    Valent P; Akin C; Nedoszytko B; Bonadonna P; Hartmann K; Niedoszytko M; Brockow K; Siebenhaar F; Triggiani M; Arock M; Romantowski J; Górska A; Schwartz LB; Metcalfe DD
    Int J Mol Sci; 2020 Nov; 21(23):. PubMed ID: 33261124
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Phase I/II study incorporating intravenous hydroxyurea into high-dose chemotherapy for patients with primary refractory or relapsed and refractory intermediate-grade and high-grade malignant lymphoma.
    Vaughan WP; Kris E; Vose J; Bierman PJ; Gwilt P; Armitage JO
    J Clin Oncol; 1995 May; 13(5):1089-95. PubMed ID: 7738614
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.